Objective: Nearly two-thirds of the population of Western and Central Europe live in countries that are iodine deficient. Damage to reproductive function and to the development of the fetus and newborn is the most important consequence of iodine deficiency. The objective of this review was to examine the iodine status of pregnant women in Europe and the potential need for iodine supplementation. Design: A MEDLINE/PubMed search and compilation of all published studies since 1990 of iodine nutrition and iodine supplementation of pregnant women in Europe, as well as an Internet-based search and review on availability and legislation of iodine supplements in the European Union. Results: Although the data suggest most women in Europe are iodine deficient during pregnancy, less than 50% receive supplementation with iodine. Mild-to-moderate iodine deficiency during pregnancy adversely affects thyroid function of the mother and newborn and mental development of the offspring and these adverse effects can be prevented or minimized by supplementation. There are no published data on the effect of iodine supplementation on long-term maternal and child outcomes. The iodine content of prenatal supplements in Europe varies widely; many commonly used products contain no iodine. The European Union is developing legislation to establish permissible levels for iodine in food supplements. Conclusions: In most European countries, pregnant women and women planning a pregnancy should receive an iodinecontaining supplement (E150 mg/day). Kelp and seaweed-based products, because of unacceptable variability in their iodine content, should be avoided. Prenatal supplement manufacturers should be encouraged to include adequate iodine in their products. Professional organizations should influence evolving EU legislation to ensure optimal doses for iodine in prenatal vitamin-mineral supplements.
Introduction
Nearly two-thirds of the 600 million people in Western and Central Europe live in regions of mild-to-severe iodine deficiency (Delange, 2002; Vitti et al, 2003) . Damage to reproductive function and to the development of the fetus and newborn is the most important consequence of iodine deficiency (Dunn & Delange, 2001) . The fetal brain is particularly vulnerable to maternal hypothyroidism in iodine deficiency, and iodine deficiency is the leading cause worldwide of preventable mental retardation (Bleichrodt & Born, 1994) . Even mild or subclinical maternal hypothyroidism during pregnancy can impair mental development of the newborn (Haddow et al, 1999; Glinoer & Delange, 2000) . This paper discusses: (a) the iodine nutrition of pregnant women and women of child-bearing age in Europe; (b) the use of iodine-containing supplements by these groups; (c) trials of iodine supplementation in pregnancy; and (d) the availability and regulation of iodine-containing supplements in Europe.
Iodine status of pregnant women
In national surveys of women of child-bearing age in European countries, median iodine intakes are approximately half of recommended levels. The recommended daily iodine intake during pregnancy from the World Health Organization/United Nations Children's Fund/International Council for Control of Iodine Deficiency Disorders (WHO/ UNICEF/ICCIDD) is 200 mg (WHO/UNICEF/ICCIDD, 2001), while the United States Institute of Medicine (IOM) suggests a Recommended Dietary Allowance (RDA) during pregnancy of 220 mg (IOM, 2001 ). The Verbundstudie Ernahrungserhebung und Risikofaktoren-Analytik (VERA) study in Germany reported a median (range) iodine intake of 100 (33-284) mg/ day in 19-24-y-old women (Bergmann et al, 1997) . Rasmussen et al (2002) found the median iodine intake in 18-22-yold Danish women in Aalborg and Copenhagen to be 85 and 116 mg/day, respectively. Even in the Netherlands, considered iodine sufficient, the National Food Consumption Survey found the mean (s.d.) iodine intake of 20-49-y-old women was 149 (36) mg/day (Brussaard et al, 1997) .
Recent studies reporting low urinary iodine (UI) in pregnant women in Europe reinforce the dietary intake data (Table 1) . UI excretion is an accurate indicator of dietary iodine intake as 490% of ingested iodine is excreted in the urine and UI is highly sensitive to recent changes in iodine intake (IOM, 2001 ). For population estimates, daily iodine intake can be extrapolated from UI by assuming 90% of ingested iodine is found in urine and a 24-h urine volume of 1.5 l (IOM, 2001) . Using this estimation, a UI of E140 mg/l would correspond to a daily intake of 200 mg iodine. During pregnancy this extrapolation may be less valid due to an increase in renal iodine clearance (Aboul-Khair et al, 1964) . In Sweden and Switzerland, two iodine-sufficient countries, UI concentrations indicate adequate dietary iodine intake during pregnancy, while in eight iodine-deficient countries (with the exception of Ireland), UI concentrations indicate that iodine intakes are clearly inadequate. Studies of thyroid size in pregnancy measured by ultrasonography also indicate iodine nutrition is suboptimal in much of Europe. In countries affected by mild or moderate iodine deficiency (Ireland, Germany, Belgium, Italy, Denmark), thyroid volume increases 14-30% during pregnancy, while in iodinesufficient countries (Finland, the Netherlands), there is no increase in thyroid volume during pregnancy (Berghout & Wiersinga, 1998; Glinoer, 2003) .
Prevalence of iodine supplementation during pregnancy and its impact on status
Studies suggest only 13-50% of pregnant women in Europe receive iodine-containing supplements. In Switzerland, although 70% of pregnant women receive a prenatal supplement, only 13% receive a supplement containing iodine; the median UI in women taking iodine-containing supplements is 194 vs 130 mg/l in nonsupplemented women (Hess et al, 2001) . In Denmark, although most pregnant women take prenatal supplements, only approx. one-third contain iodine (Nohr et al, 1993) . In Germany, only 21% of a S/C, sequential (S) or cross-sectional study (C). b Timing of urinary iodine determination. PP, postpartum. Adapted from Glinoer (2003) .
Iodine status of pregnant women in Europe M Zimmermann and F Delange pregnant women receive iodine supplements (German Ministry of Health, 1998). In both countries, median daily urinary iodine excretion is significantly higher in pregnant women supplementing with iodine than those not supplementing: 58 vs 35 mg/day in Denmark, and 85 vs 59 mg/day in Germany. In Hungary, B50% of pregnant women receive a supplement containing iodine. In those taking supplements containing Z150 mg l/day, the median UI was 115-130 mg/g cr, compared to 57-68 mg/g cr in women not supplementing (Mezosi et al, 2000) . In a cross-sectional study in Denmark, iodine supplement use (150 mg/day) and thyroid function were assessed in pregnant women and their newborns (n ¼ 144) . At term, the median UI in supplemented mothers was 60 mg/l, compared to 35 mg/l in nonsupplemented mothers. In the supplement group, thyroglobulin (Tg) in both maternal and cord blood was significantly lower, and free T4 significantly higher, compared to the nonsupplement group. Although maternal TSH was lower in the supplement group, cord TSH was 27% higher in the supplement group (Po0.05) , suggesting that, in iodine-deficient areas, the fetal thyroid may be particularly sensitive to the inhibitory effect of iodine.
Trials of iodine supplementation
Six randomized, controlled trials of iodine supplementation in pregnancy have been published, involving 450 women with mild-moderate iodine deficiency (Table 2) . Romano et al (1991) gave 120-180 mg iodine as iodized salt or control daily beginning in the first trimester to healthy pregnant women (n ¼ 35; median UI 31-37 mg/l). In the treated group, median UI increased three-fold and thyroid volume did not change. In the controls, there was no change in UI, but a 16% increase in thyroid volume. Treatment had no effect on maternal TSH. Pedersen et al (1993) randomized pregnant women (n ¼ 54) to receive either 200 mg iodine/day as KI solution or no supplement from 17 weeks to term. Median UI increased from 55 to 90-110 mg/l in treated group. Maternal thyroid volume increased 16% in the treated group vs 30% in controls (Po0.05). Maternal Tg and TSH, and cord Tg were significantly lower in the treated group. No significant differences were found between groups comparing maternal or cord T4, T3, and FT4. In a double-blind, placebo-controlled trial, Glinoer et al (1995) supplemented pregnant women (n ¼ 120; median UI 36 mg/l; biochemical criteria of excess thyroid stimulation) with 100 mg iodine/day or control from B14 weeks to term. Treatment had no significant effect on maternal or cord T3, FT4, and T3/T4 ratio. The treated women had significantly higher UI, smaller thyroid volumes, and lower TSH and Tg levels, compared to controls. Newborns of the treated group also had significantly higher UI, smaller thyroid volumes and lower Tg levels compared to controls. There was a nonsignificant 14% increase in cord serum TSH in the treated group. Liesenkötter et al (1996) reported results from a quasirandom, controlled trial of 230 mg iodine/day from 11 weeks to term in pregnant women (n ¼ 108; median UI 53 mg/g cr; goiter rate 42.5%). Median UI increased to 104 mg/g cr in treated group, and median thyroid volume was significantly lower in the newborns of the treated women compared to controls (0.7 vs 1.5 ml, respectively, Po0.005). Treatment had no significant effect on maternal TSH, T3, T4, thyroid volume, or Tg, and had no effect on newborn TSH. In a placebo-controlled, double-blind trial, gave a multinutrient supplement containing 150 mg iodine/day or control to pregnant women positive for antithyroid peroxidase antibodies (TPO-Ab) (n ¼ 66) from 11 weeks to term. Median UI was significantly higher in the treated women at term, but there were no differences in maternal TSH, FT4 or Tg between groups. There was no difference in the prevalence of antithyroglobulin antibodies (Tg-Ab) or TPOAb, and no differences in prevalence or severity of postpartum thyroid dysfunction (PPTD; defined as an abnormal TSH in the postpartum period) between groups. However, 12/20 (60%) of treated women developed PPTD compared to 11/24 (46%) of controls, and failure to detect a significant difference in PPTD prevalence may have been due to a type II error. In a prospective, randomized, open-label trial, Antonangeli et al (2002) supplemented pregnant women (n ¼ 67; median UI 74 mg/g cr) with 50 mg or 200 mg iodine/day from 18-26 to 29-33 weeks. Median UI was significantly higher in the 200 mg group than in the 50 mg group (230 vs 128 mg/g cr). However, there were no differences in maternal FT4, FT3, TSH, Tg or thyroid volume between groups, and no differences in TPO-Ab, Tg-Ab or prevalence of PPTD.
In summary, what do these trials tell us about the dose, safety and efficacy of iodine supplementation in mildmoderately iodine-deficient pregnant women? In all six trials, supplementation resulted in a significant increase in maternal UI. Iodine doses varied between 50 and 230 mg/day, and the data indicate no clear dose-response relationship for UI (Table 2) , TSH, Tg, thyroid hormones, or thyroid volume. Iodine supplements during pregnancy appear to be generally safe; there was no increase in maternal thyroid autoimmunity, or in the prevalence or severity of PPTD in the trials. However, sample sizes were small, and more data, particularly from TPO-Ab þ women, would be valuable. For the newborn, most data suggest supplementation is safe, although the studies of and Glinoer et al (1995) reported higher newborn TSH levels with supplementation. Iodine supplementation is efficacious, both for the mother and newborn. Low intakes of iodine during pregnancy cause maternal and fetal thyroid stress, characterized by increased thyroid size and Tg release in both mother and newborn. In three of the five trials that measured maternal thyroid volume, supplementation was associated with significantly reduced maternal thyroid size. The studies also suggest an increase in newborn thyroid volume and Tg can be prevented or minimized by supplementation. Although less consistent, the data also suggest maternal TSH is generally lower (within the normal reference range) with supplementation. Supplementation has little or no impact on maternal and newborn total or free thyroid hormone levels. There are no clinical data on the effect of supplementation on birth weight or prematurity, and no data on long-term outcomes, such as maternal goiter, thyroid autoimmunity, or child development.
Availability and regulation of iodine-containing supplements
The labeled iodine content of multivitamin/minerals marketed as prenatal supplements in Europe varies widely. Many commonly used products contain no iodine (eg Eunova , Twin Labs). The actual iodine content in supplements is determined not only by the original amount added, but also by the stability of the compound, the time elapsed since manufacture, and the conditions under which the product is stored. Lee et al (1994) reported on the variability of iodine content in multinutrient supplements (n ¼ 42) available in the UK. The median iodine content (range) of the manufacturer's recommended daily supplement regimen was 104 (11-171) mg/day. The mean measured iodine content (as a percent of declared content) was 79 (8-197)%, and 16% of the supplements contained o60% of their declared iodine content. The iodine content of kelp supplements, a popular supplemental form, was highly variable. The median iodine content (range) of the manufacturer's recommended daily supplement regimen was 1005 (210-3840) mg/day. The mean measured content (as a percent of declared content) was 137 (45-914)%. For half of the kelp supplements, the manufacturer's recommended daily dose was greater than 1100 mg/day, the recommended Safe Upper Limit for pregnancy (IOM, 2001 ). In addition, bioavailability of iodine from supplements has not been tested. Bioavailability can be influenced by the physical form of the product, for example, tablets vs gelatin capsule, the substance used in coating and thickness of coat, the amount of pressure used to form the tablet, the disintegration and dissolution of the tablet, and other nutrients or substances present which may interfere with bioavailability (Park et al, 1991) . There are no published data assessing iodine bioavailability from vitamin/mineral supplements.
Until recently, there was no specific European Union regulation of multivitamin/mineral supplements. They were classified as foods, and had to comply with relevant EU food legislation and individual member state's internal legislation. This resulted in wide variation across Europe in legislation, compounds allowed and permissible levels. To remedy this, the EU Parliament approved a Common Position 'On the approximation of the laws of member states relating to food supplements'(C5-0640/2001) in 2002. Its goals are to harmonize divergent national rules on sales of food supplements that contain vitamins and minerals, and to ensure food supplements are safe and properly labeled (EU Website, 2003) . Its provisions apply to all food supplements except those licensed as medicines (EU Council Directive 65/ 65/EEC) and those covered under 'foods for particular nutritional uses'(Council Directive 89/398/EEC). Provisions of the Common Position state that the label of the supplement must contain clear instructions for daily dosage, and a warning about possible health risk from excess use. Purity criteria are those specified by EU legislation for foods. Any language suggesting a varied diet does not provide necessary amounts of essential nutrients is prohibited, with the exception of 'when the need for supplementation of specific population groups is established by generally accepted scientific data'. It could be argued this exception would apply to iodine in iodine-deficient regions of Europe. Provisions specific for iodine state: (a) supplements may contain iodine; (b) the amount present should be labeled in mg; (c) the only iodine compounds permitted are potassium iodide, sodium iodide, potassium iodate, and sodium iodate. This legislation entered into force in July 2002, and EU Member States needed to enact the necessary regulations to comply with this Directive by July 2003. Permissible maximum and minimum levels for iodine in supplements will be set by the EU Standing Committee on Food no later than 2007. Regulation of nonvitamin/mineral supplements containing iodine (eg kelp tablets) is due in a second report of the Commission in 2007, and until then individual member states' laws apply.
Conclusions
Iodine status of pregnant women is clearly suboptimal in many regions in Europe, and iodine-containing supplements have a beneficial impact on the iodine and thyroid status of both the mother and newborn. Pregnant women in these regions, if not adequately covered by iodized salt, should be supplemented with iodine in the form of potassium iodide tablets or iodine-containing prenatal multivitamin prepara-tions. Another option is oral iodized oil; it is safe and its single dose is easier to administer, but it may not provide constant blood iodine levels (Delange, 1996) . Adequate iodine before conception is best, and women who are planning a pregnancy should consider iodine supplementation if iodized salt is not available. The fetus is particularly vulnerable to damage from iodine deficiency early in pregnancy (Pharoah et al, 1971; Xue-Yi et al, 1994; Delange, 2001) , and if supplementation begins only at the first prenatal care visit, this critical period may be missed. Because certain groups of women-the poor and less educated-are less likely to benefit from campaigns that encourage iodine supplementation, continued efforts for universal salt iodization remain a priority. More research to determine the optimal dose of supplemental iodine, the bioavailability of iodine from multinutrient preparations, and efficacy in terms of long-term clinical outcomes would be valuable.
Recommendations
Clinicians in European countries harboring iodine deficiency should consider recommending an iodine-containing supplement (E150 mg/day) for pregnant women and for those women planning a pregnancy. Kelp and seaweed-based products, because of unacceptable variability in their iodine content, should be avoided. Professional organizations, such as the European Thyroid Association and the European Office of ICCIDD should encourage prenatal supplement manufacturers to include adequate iodine (E150 mg/day) in their products. These organizations should also take a lead advocacy role to ensure the EU Standing Committee on Food establishes optimal minimum and maximum doses for iodine in food supplements.
